> Concomitant administration of SACITUZUMAB GOVITECAN  with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. SACITUZUMAB GOVITECAN  should be used with caution in patients receiving UGT1A1 inhibitors (e.g. PROPOFOL, KETOCONAZOLE, EGFR tyrosine kinase inhibitors). 
